Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
equine botulinum neurotoxin B immune FAB2
- Development stage
- Unknown
- Lead developer
- Cangene
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Equine botulinum neurotoxin B immune FAB2 is a biologic antitoxin preparation composed of polyclonal antibody fragments (primarily F(ab')₂) derived from the plasma of horses immunized with botulinum toxin serotype B. It is administered intravenously for the treatment of symptomatic or suspected exposure to botulinum toxin type B in adults and pediatric patients. The mechanism of action involves high-affinity binding to circulating unbound botulinum toxin type B molecules; this prevents their attachment to ganglioside anchorage sites and membrane-bound receptors on cholinergic nerve terminals. By blocking internalization into nerve cells, it neutralizes the toxic effects before they can manifest clinically. Equine-derived antitoxins are used as emergency therapy for non-infant cases of suspected or confirmed exposure to Clostridium botulinum toxins[1][5][7].
- Brand names
- BAT
- Other names
- botulinum neurotoxin B immune FAB2, equineBotulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)HBAT
02
Targets
BoNT/B (Botulinum neurotoxin type B)
Beyond the preview
Go deeper on equine botulinum neurotoxin B immune FAB2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on equine botulinum neurotoxin B immune FAB2.